Generics Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) announced second quarter financial results for 2011, with earnings up a whopping 64.7% to $56 million, or $0.17 a share and revenues of $609.4 million rocketing 155% compared $238.8 million in the like 2010 period, driven by strength in Europe, Latin America, Canada and Australia. 5 August 2011